UBS Group’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

UBS Group’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,213	Closed	-$706	–	10377
2024 Q2	$706	Buy	25,213 +4,817	+24%	+$259	﹤0.01%	8810
2024 Q1	$1.84K	Buy	20,396 +20,346	+40,692%	+$1.94K	﹤0.01%	8038
2023 Q4	$5	Buy	+50	New	+$7	﹤0.01%	9160
2023 Q2	–	Sell	-8,082	Closed	-$1.46K	–	9925
2023 Q1	$1.46K	Sell	8,082 -1,272	-14%	-$291	﹤0.01%	8734
2022 Q4	$1.87K	Sell	9,354 -30,999	-77%	-$13.3K	﹤0.01%	9776
2022 Q3	$29K	Sell	40,353 -10,223	-20%	-$6.99K	﹤0.01%	6935
2022 Q2	$27K	Buy	+50,576	New	+$32.1K	﹤0.01%	6532
2022 Q1	–	Sell	-1,220	Closed	-$3K	–	11097
2021 Q4	$3K	Buy	1,220 +714	+141%	+$2.31K	﹤0.01%	9709
2021 Q3	$2K	Buy	+506	New	+$1.8K	﹤0.01%	9011

Other funds holding DNA.WS

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's DNA.WS Position: Q3 2024 in Review

UBS Group sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 25,213 shares — an estimated $706 sold.

UBS Group first reported a position in DNA.WS in Q3 2021 and held it in 9 quarters. The position peaked at $29K in Q3 2022. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

UBS Group reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
UBS Group sold 25,213 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $706.
UBS Group first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 9 quarters.
UBS Group's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $29K in Q3 2022.
5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.